That would be something that we would look at. We would go through the normal processes for any substitution drug to be added to the formulary. We would look at the issues of efficacy and effectiveness as well as cost, but we'd also look at that. One of the overlay issues is the potential impact of that kind of drug being in an institutional setting. It's one of the factors we have to always weigh.
On November 18th, 2013. See this statement in context.